RSS

biosimilars

Filtration, separation and purification specialist, Pall, has announced a strategic partnership between its Pall Biotech business using and Aetos Biologics — a biosimilar cell line development company. more

News

The recently announced ‘Biosimilar Action Plan’ (BAP) from the US Food and Drug Administration (FDA) is another move by the regulatory body to achieve cost-effective pricing, according to an analyst at data and analytics company, GlobalData. more

News

A co-development agreement has been formed by Xbrane Biopharma and STADA Arzeneimittel for the development of Xlucane — a biosimilar to Lucentis (ranibizumab), which is mainly used for the treatment of wet age-related macular degeneration (AMD). more

News

According to CPhI Korea, the Korean pharma market is experiencing significant growth in finished drug products, which is being attributed to an expanding domestic generics market. more

Analysis

Singapore-based biopharmaceutical company, Prestige Biopharma, and privately-owned pharma company, Alvogen, have entered a license and supply agreement to commercialise trastuzumab biosimilar (Hervelous) in central and eastern Europe. more

News

Here we count down the top five tweets from @EPM_magazine that have gained the most impressions this week, taken from Twitter analytics. more

News

Catalent Pharma Solutions, a global provider of advanced delivery technologies and development solutions, and Valerius Biopharma, a Swiss biopharmaceutical company, are collaborating on the development and manufacture of speciality biosimilars more

News

Biosimilar entry onto US market is slow despite implementation of the Biologics Price Competition and Innovation Act (BPCIA) by the Food and Drug Administration (FDA), according to data and analytics company, GlobalData. more

Analysis

Data and analytics company, GlobalData, has revealed that biosimilars to Humira will have significant uptake across Europe this year as a result of 10–20% lower prices compared with the originator brand. more

Analysis

Biosimilars are increasing in popularity with pharma companies, however, an important consideration for the interested parties is knowing which markets are saturated and which are still open, according to data and analytic company, GlobalData. more

Analysis

Amgen and Allergan have received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for the marketing authorisation of ABP 980, a biosimilar to Herceptin (trastuzumab). more

News

The Mundipharma network of independent associated companies has expanded its partnership with biopharma company Celltrion Healthcare to now include exclusive distribution rights to trastuzumab biosimilar, Herzuma, in seven EU markets. more

News

According to data and analytics company, GlobalData, new real-world evidence will support the use of a biosimilar treatment for Crohn’s disease (CD), leading to a boost in the biosimilar market value. more

Analysis

Data and analytics company, GlobalData, has revealed 2017 was a record-breaking year for the number of approvals of biosimilars. more

Analysis

Data and analytics company, GlobalData, has released its findings from its review of the biopharmaceutical industry from 2017. more

Analysis

A recent report from CPhI Japan has forecast that this year, 2018, will be a transformative year for Japanese pharma as the market is expected to see growth in generics, biosimilars and internationalisation. more

Analysis

A strategy for the development of a biosimilar to the vascular endothelial growth factor (VEGF) inhibitor treatment for various degenerative retinal diseases, aflibercept, has been announced by Momenta Pharmaceuticals and Mylan. more

News

The US Food and Drug Administration (FDA) has approved Sanofi’s short-acting insulin (Admelog — insulin lispro injection) as a ‘follow on’ product to treat diabetes. more

News

Here we count down the top five tweets from @EPM_magazine that have gained the most impressions this week, taken from Twitter analytics. more

News

The US Food and Drug Administration (FDA) has approved the first biosimilar for the treatment of certain breast and stomach cancers, Ogivri (trastuzumab-dkst). more

News